04:18 PM EDT, 08/06/2024 (MT Newswires) -- Clene ( CLNN ) shares closed 47% higher Tuesday after the biopharmaceutical company said it submitted more clinical data to US regulators supporting an accelerated approval of its drug candidate to treat neurological diseases, including amyotrophic lateral sclerosis, or ALS.

The new data includes analyses from a pair of phase 2 trials, with one of the studies showing ALS patients who received long-term treatment with CNM-Au8 experienced a 57% reduction in their risk of dying. A separate testing showed an effective biomarker to measure ALS progression and mortality risk.

Clene ( CLNN ) expects to discuss the new biomarker and efficacy data for CNM-Au8 with the US Food and Drug Administration during the current quarter.

Price: 5.81, Change: -0.07, Percent Change: -1.19